Akeso Starts Phase II Trial of AK146D1 for Advanced NSCLC
HONG KONG, July 20, 2026 Akeso, Inc. has announced a significant milestone in its oncology pipeline with the first...
VEGF
Advertisement
REGENXBIO Doses First Patient in NAAVIGATE Gene Trial
ROCKVILLE, Md., June 29, 2026 REGENXBIO Inc. has reached a major milestone in the advancement of gene therapy for...
Ollin Biosciences Announces $330M Series B to Accelerate OLN324 for DME and Wet AMD
AUSTIN, TX, June 24, 2026 Ollin Biosciences has announced the successful completion of an oversubscribed $330 million Series B...
CStone’s CS2009 Delivers Strong NSCLC and CRC Results at ASCO 2026
SUZHOU, China, June 1, 2026 CStone Pharmaceuticals announced updated clinical data for CS2009, its investigational PD-1/VEGF/CTLA-4 trispecific antibody, at...
Kelun-Biotech Gains China IND Clearance for SKB118
CHENGDU, China, May 12, 2026 Kelun-Biotech announced that China’s Center for Drug Evaluation (CDE) under the National Medical Products...
Advertisements
Kodiak KSI-101 Shows Strong MESI Clinical Trial Results
Palo Alto, California, United States | May 1, 2026 Kodiak Sciences Inc. has announced new clinical and pipeline advancements...
Compass Therapeutics Nears Key Data for Tovecimig in BTC
Boston, Massachusetts | April 24, 2026 Compass Therapeutics has announced it will present topline secondary endpoint data from its...
KSI-101 Phase 1b Data Advance Inflammatory Macular Therapy
PALO ALTO, Calif., Feb. 4, 2026 —Kodiak Sciences Inc. announced that final end-of-study Phase 1b APEX clinical results evaluating...
Advertisement
